Much needed strength on the top-line both in 2Q and in the forward outlook, but at the expense of some modest margin weakness in both periods. Nothing to be too upset about though:
Keep reading with a 7-day free trial
Subscribe to Earnings Edge to keep reading this post and get 7 days of free access to the full post archives.